parkinsonhubPeople living with Parkinson’s could have their symptoms reduced by use of an alternative delivery of dopaminergic therapy via a non-oral route, according to new research.
 
The suggestion of using a subcutaneous injection is outlined in a new report that has been produced in the European Neurological Review.
 
The report suggests that the delay in levodopa coming into affect (known as morning akinesia) could be managed by one injection containing apomorphin.
 
Those living with Parkinsons often have to deal with “off” periods which is where the effects of the medication are either wearing off or have not come into effect.
 
They can also be caused by Gastroparesis which causes a delay in the emptying of a persons stomach, often more common with Parkinson’s sufferers, which slows down how quickly medication can be absorbed.
 
As a result the brain does not produce enough dopamine (the drug used to treat Parkinsons), which can cause patients to have difficult carrying out simple day-to-day tasks.
 
An in-depth look will now be carried into the use of apomorphin in the AM-IMPAKT full study which will assess how likely the drug is to help people with Parkinsons.
 
If successful then the drug could help millions who suffer from what can be, at times, a debilitating disease.

Read the study results in full at http://www.epda.eu.com/